McClarren Financial Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$624K Hold
520
0.32% 46
2026
Q1
$478K Sell
520
-1,629
-76% -$1.65M 0.28% 51
2025
Q4
$559K Buy
2,149
+1,629
+313% +$1.56M 0.33% 46
2025
Q3
$397K Hold
520
0.24% 54
2025
Q2
$405K Buy
+520
New +$404K 0.26% 50
2025
Q1
Sell
-519
Closed -$400K 335
2024
Q4
$400K Buy
+519
New +$430K 1.12% 13
2024
Q3
Sell
-1,810
Closed -$468K 309
2024
Q2
$468K Buy
1,810
+1,292
+249% +$1.03M 0.33% 45
2024
Q1
$403K Buy
518
+2
+0.4% +$1.42K 0.29% 50
2023
Q4
$301K Buy
516
+1
+0.2% +$584 0.23% 57
2023
Q3
$276K Buy
515
+63
+14% +$32.5K 0.24% 56
2023
Q2
$212K Buy
452
+1
+0.2% +$419 0.18% 61
2023
Q1
$155K Buy
451
+2
+0.4% +$675 0.14% 78
2022
Q4
$164K Buy
449
+1
+0.2% +$355 0.16% 75
2022
Q3
$145K Buy
+448
New +$142K 0.14% 73
2022
Q2
Sell
-445
Closed -$127K 158
2022
Q1
$127K Hold
445
0.09% 77
2021
Q4
$123K Buy
445
+3
+0.7% +$761 0.08% 88
2021
Q3
$102K Sell
442
-98
-18% -$24.2K 0.08% 77
2021
Q2
$124K Buy
540
+101
+23% +$20.3K 0.1% 71
2021
Q1
$82K Buy
439
+2
+0.5% +$391 0.07% 89
2020
Q4
$73K Buy
+437
New +$65.2K 0.07% 87

Other funds holding LLY

McClarren Financial Advisors's LLY Position: Q2 2026 in Review

McClarren Financial Advisors held its Eli Lilly (LLY) position steady in Q2 2026 at 520 shares worth $624K. The position accounts for 0.32% of the portfolio, ranked #46.

McClarren Financial Advisors first reported a position in LLY in Q4 2020 and has held it in 20 quarters since. 1,267 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • McClarren Financial Advisors held 520 shares of Eli Lilly worth $624K as of Q2 2026.
  • McClarren Financial Advisors left its Eli Lilly share count unchanged in Q2 2026.
  • Eli Lilly made up 0.32% of McClarren Financial Advisors's portfolio in Q2 2026, its #46 holding.
  • McClarren Financial Advisors first reported a position in Eli Lilly in Q4 2020 and has held it in 20 quarters since.
  • 1,267 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on McClarren Financial Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.